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Correlation of the Osteoarthritis Susceptibility Variants
That Map to Chromosome 20q13 With an
Expression Quantitative Trait Locus Operating on NCOA3 and
With Functional Variation at the Polymorphism rs116855380
Fiona Gee, Michael D. Rushton, John Loughlin, and Louise N. Reynard
Objective. To functionally characterize the osteoar-
thritis (OA) susceptibility variants that map to a region
of high linkage disequilibrium (LD) on chromosome
20q13 marked by the single-nucleotide polymorphism
(SNP) rs6094710 and encompassing NCOA3 and SULF2.
Methods. Nucleic acids were extracted from the
cartilage of OA patients. Overall and allelic expression of
NCOA3 and SULF2 were measured by quantitative reverse
transcription–polymerase chain reaction and pyrose-
quencing, respectively. The functional effect of SNPs with-
in the 20q13 locus was assessed in vitro using luciferase
reporter constructs and electrophoretic mobility shift
assays (EMSAs). The in vivo effect of nuclear receptor
coactivator 3 (NCOA3) protein depletion on primary
human OA articular cartilage chondrocytes was assessed
using RNA interference.
Results. Expression of NCOA3 correlated with the
genotype at rs6094710 (P5 0.006), and the gene demon-
strated allelic expression imbalance (AEI) in individuals
heterozygous for the SNP (mean AEI 1.21; P < 0.0001). In
both instances, expression of the OA-associated allele was
reduced. In addition, there was reduced enhancer activity
of the OA-associated allele of rs116855380, a SNP in
perfect LD with rs6094710 in luciferase assays (P < 0.001).
EMSAs demonstrated a protein complex binding with
reduced affinity to this allele. Depletion of NCOA3 led
to significant changes (all P < 0.05) in the expression of
genes involved in cartilage homeostasis.
Conclusion. NCOA3 is subject to a cis-acting expres-
sion quantitative trait locus in articular cartilage, which
correlates with the OA association signal and with the OA-
associated allele of the functional SNP rs116855380, a SNP
that is located only 10.3 kb upstream ofNCOA3. These find-
ings elucidate the effect of the association of the 20q13
region on OA cartilage and provide compelling evidence of
a potentially causal candidate SNP.
Osteoarthritis (OA) is a common, multifactorial
disease characterized by progressive focal loss of articular
cartilage, which can be accompanied by changes in the
function of other tissues in the joint (1). Genetics is a
major risk factor for OA and acts via a large number of
susceptibility alleles of small individual effect sizes (2).
Several recent genome-wide association studies
(GWAS) have identified susceptibility loci for OA (3–5),
including a recent meta-analysis of .78,000 European
subjects in whom a genome-wide significant signal associ-
ated with hip OA was identified (6). This signal, at chro-
mosome 20q13, was marked by the single-nucleotide
polymorphism (SNP) rs6094710 (G/A) (P5 7.9 3 102 9;
odds ratio 1.28). This SNP is moderately rare, with a
minor allele frequency (MAF) of 0.04 (4%) in Europeans.
It is located upstream of NCOA3 and SULF2, genes that
encode nuclear receptor coactivator 3 and extracellular
heparan sulfate 6-O-endosulfatase 2, respectively. Expres-
sion of NCOA3 is reduced in OA cartilage compared to
preserved cartilage from the same joint (6), whereas
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SULF2 expression is increased in OA cartilage compared
to normal articular cartilage (7).
The SNP rs6094710 is in perfect linkage disequilib-
rium (LD) (r25 1, D05 1) with 11 other SNPs within the
20q13 region. There are no other SNPs with an r2 value of
.0.6 with these 12 SNPs. This strongly implies that the
association signal is mediated by 1 of the 12 SNPs, all of
which encompass a region of 194 kb that includes all
of NCOA3 and approximately two-thirds of SULF2. One
of the 12 SNPs, rs6094752, is a missense SNP leading to
an amino acid change (Arg.Cys) at position 218 in the
NCOA3 protein (6). However, this substitution is
predicted to be benign, according to a study in which pre-
diction tools were used (8).
The vast majority of risk alleles for common dis-
eases modulate susceptibility by acting as expression quan-
titative trait loci (eQTLs), which influence the expression
or stability of a transcript (9–11). In OA, an excellent exam-
ple is rs143383, which is located in the 5 0-untranslated
region of GDF5; the T allele of this SNP correlates with
reducedGDF5 expression in the joint tissue of OA patients
(12). We hypothesized, therefore, that the association with
OA susceptibility marked by rs6094710 is an eQTL that
acts onNCOA3 and/or SULF2, and the functionality of this
eQTL can be directly linked to either rs6094710 or 1 of the
11 SNPs that are in perfect LD with it. We tested this
hypothesis by examining both overall gene expression and
allelic expression of NCOA3 and SULF2 in cartilage tissue
fromOApatients, and then used a number of experimental
methods to further pursue the identified functionality.
PATIENTS AND METHODS
Patients. The Newcastle and North Tyneside research
ethics committee (REC) granted ethics approval (REC reference
no. 09/H0906/72) to obtain cartilage tissue from patients with pri-
mary OA undergoing elective hip or knee replacement. Informed
consent was obtained from each donor. Full-thickness, macro-
scopically normal articular cartilage away from the OA lesion was
collected. Further information regarding the 65 patients is provid-
ed in Supplementary Table 1 (available on the Arthritis & Rheu-
matology web site at http://onlinelibrary.wiley.com/doi/10.1002/
art.39278/abstract). Nucleic acids were extracted and complementa-
ry DNA (cDNA) was synthesized as previously described (13,14).
Evaluation of gene expression. Gene expression was
assessed by quantitative real-time reverse transcription–polymerase
chain reaction (RT-PCR) using an ABI Prism 7900HT Se-
quence Detection System (Applied Biosystems). NCOA3 reac-
tions were performed using a TaqMan Gene Expression Assay
(Hs01105251_m1; Applied Biosystems). All other reactions were
performed using PrimeTime quantitative PCR assays (Integrated
DNA Technologies). A list of the primer and probe sequences
used for RT-PCR is available in Supplementary Table 2 (avail-
able on the Arthritis & Rheumatology web site at http://online
library.wiley.com/doi/10.1002/art.39278/abstract). For each cDNA
sample, 3 pipetting replicates were performed to determine the
expression levels of each gene. These expression levels, relative to
those of the housekeeping genes 18S,GAPDH, andHPRT1, were
calculated using the formula 22DCt . Outliers were removed from
the data using Grubbs’ test (15). P values were calculated using a
Mann-Whitney 2-tailed exact test.
Transcript SNP selection and allelic expression ana-
lysis. The SNP rs6094752 was used for NCOA3, since this tran-
script SNP is in perfect LD with rs6094710. It is located in exon
7 of the gene. The SNP rs3810526 was used for SULF2, since
this transcript SNP has the highest pairwise LD with rs6094710
(r25 0.006, D05 0.40). The SNP rs3810526 is a G/A amino acid
transition, has an MAF of 0.34 in Europeans, and is located in
exon 3 of SULF2.
Allelic expression imbalance (AEI) was determined as
previously described (16). Standard PCR, using a G-Storm GS4
Q4 Quad Block Thermal Cycler (Somerton Biotechnology Cen-
tre), was used to amplify the rs6094752 and rs3810526 regions
with biotinylated primers, creating biotinylated PCR products.
Samples were then analyzed on a PyroMark Q24 MDx platform
(Qiagen) using a PyroMark Gold Q96 Reagents kit, in accor-
dance with the manufacturer’s instructions. The primers used for
each SNP, including the sequencing primers, were obtained from
Sigma-Aldrich (a list is provided in Supplementary Table 2,
available on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.39278/abstract) and were
designed to reside within single exons. Sequences were generated
automatically, and an output of allelic ratio was produced using
PSQ 96 SQA software (Qiagen).
For each patient, samples were analyzed in triplicate,
cartilage cDNA and cartilage DNA were analyzed concurrently,
and allelic expression of cDNA was normalized to that of its cor-
responding DNA. Accurate discrimination of SNP alleles was
verified using artificially created allelic expression ratios derived
from DNAs of known genotype. P values for each SNP were cal-
culated by comparing DNA allelic expression ratios to cDNA
allelic expression ratios. Comparisons were made using a Mann-
Whitney 2-tailed exact test. In addition, pyrosequencing was
used to genotype rs6094710.
Construction of luciferase reporter plasmids, cell cul-
tures, and luciferase assays. Two online databases were
searched to identify SNPs within the 20q13 region that are in LD
with rs6094710: the Broad SNAP database, which encompasses
data from the 1000 Genomes project (http://www.broadinstitute.
org/mpg/snap/), and the HapMap database (http://hapmap.ncbi.
nlm.nih.gov). To generate the constructs for use in the luciferase
reporter gene assay, primers containing either anMlu I or an Xho
I restriction enzyme site toward their 5 0 ends were designed to
amplify DNA regions encompassing each of the 12 SNPs. Primer
sequences are listed in Supplementary Table 3 (available on the
Arthritis & Rheumatology web site at http://onlinelibrary.wiley.
com/doi/10.1002/art.39278/abstract). Template DNA consisted of
a mix of DNA from 4 patients heterozygous for rs6094710.
PCR products were purified using a QIAquick PCR
purification kit (Qiagen) and cloned into the pGL3-promoter
luciferase reporter plasmid (Promega) using theMlu I and Xho
I restriction sites. Positive clones were sequenced to ensure the
correct sequence of the constructs. The SW1353 human chon-
drosarcoma cell line and the SW872 human liposarcoma cell
line (both from ATCC) were transfected for the luciferase
assays. Twenty-four hours before transfection, SW1353 cells
were seeded at a density of 6,000 per well, while SW872 cells
were seeded at a density of 10,000 per well, in a 96-well plate.
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Cells were transfected with 50 ng of pGL3 construct DNA and
30 ng Renilla luciferase reporter vector pRL-TK (Promega),
using FuGene HD transfection reagent (Promega). After 24
hours, the cells were lysed and luciferase activity was deter-
mined using a Dual-Luciferase Reporter Assay System (Pro-
mega). Luminescence was measured using a GloMax-Multi
Detection System (Promega). Firefly luciferase activity was
normalized to the activity of Renilla luciferase. Six technical
and 6 biologic repeats were performed per cell line per con-
struct. P values were calculated using a Mann-Whitney 2-tailed
exact test.
Electrophoretic mobility shift assays (EMSAs). The
JASPAR, PROMO, and TFSearch online databases were used to
predict protein binding to the A and G alleles of rs116855380
(17–19). Nuclear protein was extracted from SW1353 and SW872
cells as previously described (20). Forward and reverse single-
strandedDY682-labeled oligonucleotides (EurofinsMWGOper-
on) for both alleles, spanning 15 bp to each side of rs116855380,
were annealed to generate double-stranded probes, and EMSAs
were performed as previously described (20).
All EMSA experiments were performed twice. Briefly,
binding reactions were performed for 20 minutes at room tem-
perature using an Odyssey EMSA buffer kit (LiCor Biosciences).
Each reaction contained 5 mg nuclear extract, 200 fmoles
annealed oligonucleotide, 13 Binding Buffer, 2.5 mM dithio-
threitol, 0.5 mg poly(dI-dC), and 10 mM EDTA. Samples were
separated on a 5% (weight/volume) native polyacrylamide gel in
0.53 Tris–borate–EDTA for 4 hours at 100 volts, followed by
visualization with an Odyssey Infrared Imager (LiCor Bioscien-
ces). For competition assays, unlabeled oligonucleotides identical
to the probes, or containing a transcription factor consensus
sequence, were added to the binding reaction in excess. For
supershift assays, 2 mg or 6 mg of antibody was added to the bind-
ing reaction. All probe and competitor sequences and antibodies
used in the EMSAs are listed in Supplementary Tables 4 and 5
(available on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.39278/abstract).
Immunohistochemistry. Macroscopically normal carti-
lage away from the OA lesion was fixed overnight in 10% forma-
lin (Sigma-Aldrich) and wax embedded. Sections were cut and
stained using anti-NCOA3 antibody (ab133611; Abcam). Briefly,
sections were incubated in boiling citrate, pH 6.0, for 6 minutes,
washed in Tris buffered saline for 5 minutes, and stained using
an ImmPRESS Anti-Rabbit Ig Reagent Kit (Vector Laborato-
ries), in accordance with the manufacturer’s instructions. Primary
antibody was applied for 30 minutes at a 1:150 dilution, diamino-
benzidine was used as the peroxidase substrate, and hematoxylin
was used to counterstain.
RNA interference. Primary human articular chondro-
cytes (HACs) were isolated by enzymatic digestion of OA carti-
lage and cultured as described previously (21). HACs were
seeded 24 hours before transfection with 100 nM Dharmacon
ON-TARGETplus SMARTpool small interfering RNA (siRNA)
targeted against NCOA3 (L-003759-00) or an ON-TARGETplus
nontargeting siRNA control pool (D-001810-10-20), using
DharmaFECT 1 transfection reagent (Dharmacon). After 48
hours, gene expression was assessed byRT-PCR, and protein levels
were assessed by immunoblotting. For RT-PCR, cells were seeded
at a density of 10,000 cells perwell in a 96-well plate, with 6 technical
repeats per treatment. Forty-eight hours after transfection, the 96-
well plate was used to synthesize cDNA using a Cells-to-cDNA II
kit (Ambion), and gene expressionwas assessed byRT-PCR.
For immunoblot analysis, cells were seeded at a density
of 350,000 cells per well in a 6-well plate. Two wells were seeded
per treatment and their contents combined before protein
extraction. Total protein was extracted from the 6-well plate
using a spin column extraction kit (Nucleospin RNA/Protein;
Macherey-Nagel, supplied by Fisher), in accordance with the
manufacturer’s instructions. Three biologic repeats were per-
formed using cells obtained from 3 individual OA patients.
P values were calculated using a Student’s 2-tailed t-test.
Immunoblotting. To assess depletion of NCOA3, total
protein fromHACswas quantified (Bradford reagent; Expedeon)
and 10 mg was resolved on 12% (w/v) sodium dodecyl sulfate–
polyacrylamide gels. Protein was transferred to Immobilon-P
PVDF membranes (Merck Millipore). Anti-NCOA3 antibody
(ab133611;Abcam)was used at a 1:1,000 dilution to assess protein
levels. A b-actin antibody (A5316; Sigma) was used at a 1:10,000
dilution as a loading control. Depletion of NCOA3was quantified
using ImageJ software (22), and NCOA3 levels were normalized
to the levels of b-actin for each treatment condition.
RESULTS
Quantitative expression of NCOA3 and SULF2
in OA cartilage stratified by rs6094710 genotype. To
determine whether the 20q13 locus harbors a cartilage
eQTL that correlates with the OA association signal, we
quantified the expression levels of NCOA3 and SULF2 in
articular cartilage samples from patients with OA and
stratified the data by genotype at rs6094710. Although
rs6094710 is associated only with hip OA, we performed
our analyses in both hip and knee tissue in order to deter-
mine whether the functional variant operates in knee as
well as hip tissue. Since this SNP has a moderately low
MAF (0.04), none of our patients were homozygous for
the minor allele of the SNP. Our comparisons therefore
involved an analysis of GG homozygotes versus GA
heterozygotes.
We observed a significant correlation between
NCOA3 expression and genotype (Figure 1A), with pres-
ence of the minor A allele of the SNP correlating with
reduced gene expression (P5 0.006). The A allele of
rs6094710 has been found to be more common in OA
patients compared to controls (6).
We next separated the OA patients into those
with knee OA (Figure 1A) and those with hip OA (Figure
1A). We observed a significant correlation between
NCOA3 expression and genotype both in patients with
knee OA and in patients with hip OA (P5 0.03 and
P5 0.02, respectively).
Finally, we stratified NCOA3 expression by joint
site, by sex, and by age at the time of joint replacement.
We found no correlations between the level of NCOA3
expression and any of these 3 parameters (all P . 0.05;
results in Supplementary Figure 1, available on the
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Arthritis & Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.39278/abstract).
There was no correlation between rs6094710 geno-
type and SULF2 expression (P5 0.11) (Figure 1B). We
repeated the analysis after separating patients into those
with knee OA (Figure 1B) and those with hip OA (Figure
1B). Again, there was no correlation between rs6094710
genotype and SULF2 expression in patients with knee OA
or those with hip OA (P5 0.12 and P5 0.41, respectively).
When we stratified SULF2 expression by joint site, by sex,
and by age at the time of joint replacement, we found that
there was greater gene expression in the hip than in the
knee (P5 0.04) and there was increased expression of
SULF2 in women compared to men (P5 0.04), but there
was no correlation with age (P5 0.33) (results in Supple-
mentary Figure 1, available on theArthritis & Rheumatology
web site at http://onlinelibrary.wiley.com/doi/10.1002/
art.39278/abstract).
Overall, our analysis revealed an eQTL operat-
ing on NCOA3 that correlated with the OA association
signal. Moreover, we found that the OA risk allele was
mediating the reduced expression of the gene.
AEI analysis of NCOA3 and SULF2 in OA car-
tilage. We further investigated the eQTL by AEI analy-
sis, which measures the messenger RNA (mRNA) output
from each allele of a SNP in heterozygous individuals. For
NCOA3, we used transcript SNP rs6094752, which is in
perfect LD (r25 1, D05 1) with the OA-associated SNP
rs6094710. We genotyped 130 patients for whom DNA
and RNA samples were available, and identified 8 individ-
Figure 1. Columnar scatter plots of the quantitative expression of NCOA3 (A) and SULF2 (B) in osteoarthritis (OA) cartilage, stratified by genotype
at the OA-associated single-nucleotide polymorphism rs6094710. In cartilage samples from all OA patients (left), patients with knee OA (center),
and patients with hip OA (right), the expression of each gene was assessed by quantitative real-time reverse transcription–polymerase chain reaction,
with values normalized to the values for the housekeeping genes 18S, GAPDH, and HPRT1. Individual symbols represent the average of the 3 repli-
cates for each sample; horizontal lines represent the mean6SEM. P values were calculated by Mann-Whitney 2-tailed exact test.
Figure 2. Allelic expression analysis in cartilage samples from osteo-
arthritis (OA) patients. Allelic expression was assessed using the tran-
script single-nucleotide polymorphisms rs6094752 in NCOA3 (black
bars) and rs3810526 in SULF2 (gray-shaded bars). Allelic expression
of cDNA was normalized to that of its corresponding DNA. Data are
presented as a ratio of expression of the major allele over that of the
minor allele; thus, a value above 1 means that there is more of the
major allele. Samples are grouped according to OA joint site (knee [K]
or hip [H]), with the numbers of patients shown. Bars show the
mean6SEM.
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uals heterozygous for rs6094710. For SULF2, we chose
the transcript SNP rs3810526, which has the highest pair-
wise LD with rs6094710. This LD is nevertheless low
(r25 0.006, D05 0.40), and this, along with the low MAF
of rs6094710, meant that we were able to identify only 3
compound heterozygous patients among our cohort.
Cartilage from 6 patients with knee OA and 2
patients with hip OA was analyzed for AEI at
rs6094752, with the T allele (equivalent to the rs6094710
A allele) showing reduced expression in 7 patients (Fig-
ure 2). The mean fold difference in allelic expression
was 1.21, indicating that the C allele of the SNP corre-
lated with 21% more NCOA3 expression than the OA-
associated T allele (P , 0.0001).
Cartilage from 2 patients with knee OA and 1
patient with hip OA was analyzed for AEI at rs3810526.
One of the 3 patients (patient 58) showed increased
expression of the A allele (Figure 2). The mean fold dif-
ference in allelic expression was 0.93, indicating that the
A allele of the SNP produced 7% more SULF2 than the
G allele (P5 0.04).
Overall, the AEI data confirmed that the risk allele
of the OA association signal correlated with reduced
expression of NCOA3.
Identifying rs116855380 as a functional SNP. As
already noted, rs6094710 is in perfect LD with 11 SNPs
within the 20q13 OA locus (for details regarding the physi-
cal location of the SNPs, see Table 1; a visual representa-
tion of the locus can be found in Supplementary Figure 2,
available on theArthritis & Rheumatologyweb site at http://
onlinelibrary.wiley.com/doi/10.1002/art.39278/abstract).
There are no other SNPs within the region showing LD at
Table 1. Luciferase gene reporter assays in SW1353 and SW872 cell lines of the single-nucleotide polymorphisms (SNPs)
in perfect linkage disequilibrium with rs6094710*
SNP, allele
(major, minor)
SNP
location
Predicted
enhancer
SW1353 cells SW872 cells
Luciferase
activity
Fold difference
(major/minor) P
Luciferase
activity
Fold difference
(major/minor) P
rs6094710
G Intergenic Yes 3.8 1.1 0.79 5.3 1.0 0.87
A 3.5 5.1
rs73122077
C Intergenic Yes 1.0 1.0 0.32 1.4 1.1 0.015
T 1.0 1.3
rs6090683
G Intergenic Yes 1.3 1.1 0.67 1.4 1.2 0.069
C 1.2 1.2
rs6090684 Intergenic Yes 1.3 0.013 0.9 0.043
G 0.9 0.9
A 0.7 1.0
rs116855380
A Intergenic Yes 1.4 1.2 0.0003 1.6 1.5 ,0.0001
G 1.2 1.1
rs117212926
G Intronic
(NCOA3)
No 0.6 0.9 0.53 1.3 0.9 0.71
A 0.7 1.5
rs72662711
T Intronic
(NCOA3)
Yes 1.1 1.0 0.99 2.0 1.5 0.0014
C 1.0 1.3
rs6090704
G Intronic
(NCOA3)
Yes 1.0 0.9 0.61 1.6 1.2 0.027
A 1.1 1.3
rs6094752
C Exonic
(NCOA3)
No 0.8 1.1 0.70 2.0 1.1 0.33
T 0.8 1.8
rs72645259
T Intronic
(NCOA3)
No 2.3 0.9 0.34 2.6 0.7 0.0021
C 2.6 4.0
rs73913405
C Intronic
(SULF2)
Yes 0.7 1.0 0.15 1.3 1.0 0.76
T 0.6 1.3
rs73913406
T Intronic
(SULF2)
Yes 1.5 1.5 ,0.0001 1.2 1.2 0.13
G 1.0 1.0
* Luciferase activity was calculated as the activity of firefly luciferase relative to Renilla luciferase, with results normalized to
the values in empty vector. P values were calculated by Mann-Whitney 2-tailed exact test.
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an r2 value of.0.6. To assess whether rs6094710 or any of
the other 11 SNPs are functional, we cloned the regions of
DNA containing each SNP separately into a luciferase
reporter plasmid. We created both allelic forms for each
SNP and performed reporter gene expression assays using
the SW1353 and SW872 cell lines.
In SW1353 cells, we observed significant allelic
differences (P , 0.05) in luciferase activity for 3 SNPs,
while in SW872 cells, we observed significant differences
in luciferase activity between the alleles of 6 SNPs
(Table 1). Of all the SNPs tested, only 2 of the SNPs,
rs116855380 and rs6090684, showed significant differ-
ences in both cell lines. However, the allelic differences
observed for rs6090684 acted in opposite directions
between the 2 cell lines.
The region of DNA containing rs116855380 dis-
played enhancer activity in both cell lines when the A
allele of the SNP was present, and the presence of the G
allele was associated with a significant decrease in report-
er activity in SW1353 cells (P5 0.0003) (Figure 3A) and
SW872 cells (P , 0.0001) (Figure 3B). The G allele of
rs116855380 is in perfect LD with the OA-associated A
allele of rs6094710; thus, these findings from luciferase
reporter assays supported the findings from analyses of
NCOA3 expression and AEI.
EMSA assessment of trans-acting factors bind-
ing to rs116855380. An analysis of ENCODE data
sets (http://genome.ucsc.edu/ENCODE/) revealed that
rs116855380 is predicted to lie within a region of enhancer
activity (23), a prediction that was supported by the find-
ings from our luciferase assays. We therefore investigat-
ed protein complex binding to rs116855380 using
nuclear protein extracted from SW1353 and SW872
cells and using fluorescence-labeled A and G allele
probes representing the 2 alleles of this SNP (results in
SW1353 cells shown in Figure 4A; results in SW872 cells
shown in Supplementary Figure 3, available on the Arth-
ritis & Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.39278/abstract).
Figure 4. Electrophoretic mobility shift assay (EMSA) analyses in SW1353 cells. A, Increasing concentrations of unlabeled A and G allele com-
petitor were added to the EMSA reaction containing cell nuclear extract and the A and G allele probes. Arrow indicates the specific complex
binding to the probes. B, Increasing concentrations of hepatic leukemia factor (HLF) and transcription factor 4 (TCF-4) unlabeled consensus
competitors were added to the EMSA reaction containing the A or G allele probe. Arrow indicates the complex that is competed.
Figure 3. Results of luciferase reporter assays for the major A allele
and minor G allele of rs116855380 in SW1353 cells (A) and SW872
cells (B), assessing firefly luciferase activity relative to Renilla lucifer-
ase activity, normalized to an empty pGL3-promoter vector (indicat-
ed by the broken line). Bars show the mean6SEM fold change
from 6 biologic repeats, each with 6 technical replicates. P values
were calculated by Mann-Whitney 2-tailed exact test.
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We observed a similar pattern of protein com-
plex binding to the 2 probes in SW1353 cells. We tested
the specificity of the assay by adding unlabeled A and G
allele competitors, and found that one complex bound
specifically to the rs116855380 probes (Figure 4A).
Binding of this complex to both probes was outcom-
peted with a lower concentration of the A allele compet-
itor than that of the G allele competitor. For example,
Figure 4A shows that a lower concentration of the A
allele competitor, as compared to the G allele competi-
tor, was required to outcompete the A allele probe. The
addition of the A allele competitor at 253 and 503 con-
centrations resulted in the complete disappearance of
the complex (Figure 4A), whereas these same concen-
trations of the G allele competitor resulted in only a
reduction in the intensity of these bands (Figure 4A).
The same effect could be observed in SW872 cells and
in repeated experiments (results in Supplementary
Figure 3, available on the Arthritis & Rheumatology web
site at http://onlinelibrary.wiley.com/doi/10.1002/art.39278/
abstract).
Using the online databases JASPAR, PROMO,
and TFSearch, we identified 5 transcription factors (tran-
scription factor 4 [TCF-4], lymphoid enhancer–binding
factor 1 [LEF-1], hepatic leukemia factor [HLF], serum
response factor [SRF], and myocyte enhancer factor 2C
[MEF-2C]) predicted to bind to the region containing
rs116855380. We refined the number of potential factors
using competitors containing the consensus binding
sequence of each factor (the list of competitor sequences
is provided in Supplementary Table 4, available on the
Arthritis & Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.39278/abstract).With theaddition
of an HLF competitor, complex binding to both probes was
reduced, and this effect was observed with nuclear extract
from both cell lines (results in SW1353 cells shown in
Figure 4B; results in SW872 cells shown in Supplementary
Figure 3, available on the Arthritis & Rheumatology
website at http://onlinelibrary.wiley.com/doi/10.1002/art.
39278/abstract). In experiments using SW1353 cell nuclear
extract, when a TCF-4 competitor was added, complex
binding to both probes was competed (Figure 4B). Little
Figure 5. Effects of NCOA3 depletion on expression of genes involved in cartilage homeostasis. Knockdown of NCOA3 was performed in prima-
ry human articular chondrocytes obtained from 3 patients with osteoarthritis. A, Expression levels of NCOA3 mRNA in cells following NCOA3
knockdown with small interfering RNA (siRNA) targeting NCOA3 (siNCOA3). Values are the mean and SEM percentage change in mRNA
expression relative to that with the control nontargeting siRNA (siControl) (set at 100%). B, Representative immunoblot demonstrating NCOA3
depletion following siNCOA3 treatment; b-actin was used as a loading control. C, Fold change in expression of COL2A1, MMP13, and RUNX2
following siNCOA3 treatment. Values are the mean6SEM fold change relative to that with the siControl (set at 1.0), from 3 biologic repeats,
each with 6 technical replicates. P values were calculated by Student’s 2-tailed t-test. *5P , 0.05; ***5P , 0.001 versus siControl.
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or no competition was observed when the TCF-4 competi-
tor was usedwith SW872 cell extract.
Addition of antibodies targeting TCF-4 or HLF
did not result in a supershift of the specific complex (data
not shown). Through literature searches, we identified 2
transcription factors closely related to HLF (DNA bind-
ing protein and CCAAT/enhancer binding protein) that
have very similar consensus binding sites (24). However,
addition of antibodies to these proteins also did not result
in supershift of the complex (data not shown).
Regulation of COL2A1, RUNX2, and MMP13
transcriptional activity by NCOA3. To assess the pres-
ence and distribution of NCOA3 protein, we stained carti-
lage tissue prepared from nonlesional OA cartilage with an
anti-NCOA3 antibody (details shown in Supplementary
Figure 4, available on the Arthritis & Rheumatology web
site at http://onlinelibrary.wiley.com/doi/10.1002/art.39278/
abstract). The protein is present in chondrocytes in both
knee and hip cartilage. Cells within the superficial andmid-
dle zones stained more strongly than cells in the deep zone.
Staining was nuclear, consistent with the role of NCOA3 as
a coactivator of various nuclear receptors (25,26).
To investigate the role of NCOA3 in maintaining
healthy cartilage, we analyzed the effect of NCOA3
depletion by RNA interference in HACs isolated from
nonlesional areas of the OA cartilage. The depletion of
NCOA3 mRNA (75% reduction) was confirmed by RT-
PCR, and the depletion of NCOA3 protein (76% reduc-
tion) was confirmed by immunoblotting (Figures 5A and
B). We assessed the levels of 5 chondroprotective/anabolic
genes (COL1A1, COL2A1, ACAN, SOX9, and TIMP1)
and 4 genes involved in cartilage hypertrophy/catabolism
(RUNX2, ADAMTS5,MMP1, andMMP13). Expression of
COL2A1 was significantly increased following NCOA3
depletion (P5 0.02) (Figure 5C), whereas expression of
MMP13 and RUNX2 was significantly decreased (P5 0.03
and P5 0.0002, respectively) (Figure 5C).
DISCUSSION
In this study, we demonstrated the presence of a
cartilage eQTL operating on NCOA3 that correlates with
the OA association signal marked by SNP rs6094710. The
OA risk allele, the A allele of the SNP, was associated
with reduced expression of the gene. We then uncovered
allelic functionality at rs116855380, a SNP in perfect LD
with rs6094710; the G allele of rs116855380 segregated
on the same molecule as the A allele of rs6094710 in the
haplotype that harbors these 2 SNPs. Knockdown of
NCOA3 highlighted the important functional role of this
protein in chondrocyte biology. As far as we are aware,
this is the first study in which an OA association signal
derived from a GWAS has been characterized to the
point at which the functional effect has been elucidated
and a compelling causal candidate SNP identified.
Although rs6094710 has been demonstrated to be
associated with OA of the hip, we found that the eQTL
operates in both hip and knee cartilage. Many OA risk
loci show joint-specific genetic effects (2), highlighting the
complex nature of OA susceptibility and the fact that
pathophysiologic causes are not uniform across skeletal
sites (27). Presumably, lowered NCOA3 levels have a
markedly detrimental effect in the hip but not in the knee.
The OA risk marked by rs6094710 did not corre-
late with differential expression of SULF2. We did observe
a small degree of AEI in 1 of our 3 compound heterozy-
gous patients. We cannot prove a negative, and it may be
that there is an eQTL operating on SULF2. There is, how-
ever, no compelling evidence in our study to indicate that
altered expression of this gene correlates with the OA
association signal.
The SNP rs116855380, which we discovered as the
likely mediator of the NCOA3 eQTL, is located only 10.3
kb upstream of the gene, in a region that, according to
ENCODE, has a transcriptional regulatory function. We
investigated trans-acting factors that may bind differentially
to the 2 alleles of rs116855380, and which could therefore
be involved in mediating the allelic expression imbalance.
In EMSA analysis, we showed that the consensus binding
sites for TCF-4 and HLF competed with the rs116855380
probe for binding of a specific complex, which bound with
more affinity to the A allele of the SNP. We were, how-
ever, unable to observe a supershift. This suggests that
another protein with a similar consensus sequence is bind-
ing to rs116855380 and promoting transcriptional activa-
tion, and that this binding, and therefore activation, is
strongest for the A allele of rs116855380.
Other SNPs within the locus showed significant dif-
ferences in the reporter assays. We therefore cannot dis-
count the possibility that one or more of these SNPs could
also have functional effects in the cartilage tissue. How-
ever, and unlike rs116855380, the reporter assay effects of
these other SNPs were not observed in both cell types
examined or in the same direction in both cell types. Our
study has therefore enabled us to prioritize rs116855380 as
a SNP with consistent in vitro allelic functional effects that
match the findings in our OA cartilage tissue.
In our analysis of primary HACs in monolayer, a
reduction in NCOA3 protein, which mimics the genetic
effect identified, resulted in an increase in COL2A1
expression and a decrease in RUNX2 and MMP13 ex-
pression. In this model system, NCOA3 is therefore
functional. However, these results are paradoxical when
we consider that reduced expression of NCOA3 is associ-
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ated with OA risk. Although COL2A1 expression has
been shown to increase in OA cartilage, probably as a
compensatory mechanism (28,29), the expression of
RUNX2 and MMP13 has also been found to increase
(30,31), with RUNX2 directly up-regulating MMP13
(31,32). Thus, one would expect to see an increase in
RUNX2 and MMP13 expression when reducing the level
of NCOA3 protein in chondrocytes.
Our results are, however, consistent with previous
findings that showed that NCOA3 directly regulates tran-
scription ofMMP13 through coactivation of activator protein
1 and polyomavirus enhancer activator 3 (33). In addition, as
NCOA3 is a coactivator for several nuclear hormone recep-
tors, and RUNX2 transcription is activated by parathyroid
hormone (34), NCOA3may also act in this capacity to regu-
late RUNX2, and therefore MMP13, expression. NCOA3
can also recruit the nuclear factors p300/CREB binding pro-
tein–associated factor (P/CAF) and CREB binding protein
to create multisubunit coactivator complexes (25), and
P/CAF has been shown to increase RUNX2 activity by acet-
ylation (35). To clarify the role of NCOA3 in cartilage biolo-
gy, more detailed functional analyses are clearly merited,
encompassing gene overexpression and knockdown and the
use of cells in monolayer and in 3-dimensional cultures, the
latter more accurately reflecting cartilage tissue.
In conclusion, we have identified a SNP and a
functional effect that are likely to account for the OA
association mapped to chromosome 20q13: rs116855380
and differential allelic expression in NCOA3 in OA car-
tilage. Further functional analyses of the SNP, the gene,
and its protein are now justified to fully comprehend
how this particular genetic risk increases disease suscep-
tibility and how that susceptibility can be mitigated.
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